Clinical trials: Coronavirus Infection
COVID-19
A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
The aim of this phase 2 study is to evaluate the safety and efficacy of single dose IV infusion of BRII-196 and BRII-198 given as combination therapy in patients with severe COVID-19, and mild to moderate COVID-19 and…
- Trial name
- NCT04787211
- Testing
- BRII-196 and BRII-198
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Brii Biosciences Limited
SARS-CoV-2, Influenza A
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 \& Flu A/B tests at point of care sites.
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
- Trial name
- ITAP1489 (NCT05787444)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B
- Where
- United States
- Volunteers
- 1,081 people
- Sponsor
- LumiraDx UK Limited
Pneumonia, Viral, Covid-19
Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial
This is an open label clinical study to evaluate the activity of chloroquine phosphate in patients with SARS-CoV-2 virus infection.
- Trial name
- HOPE (NCT04344951)
- Testing
- UNIKINON (Chloroquine phosphate) 200mg tablets
- Where
- 8 sites in Greece
- Volunteers
- 29 people
- Sponsor
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
COVID-19
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
This study is a randomized and controlled Phase IV clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05107557
- Testing
- Experimental Group
- Where
- 2 sites in China
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Coronavirus
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Popular title: Clinical study of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells). Purpose of the study: Main objectives: To evaluate the immunogenicity and safety of Omicron BA.4/5-Delta…
- Trial name
- NCT06025812
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel coronavirus protein vaccine (CHO cells)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney…
- Trial name
- REDPINE (NCT04745351)
- Testing
- Remdesivir, Standard of Care
- Where
- 63 sites in United States, Brazil and 4 more
- Volunteers
- 249 people
- Sponsor
- Gilead Sciences
Continuous Renal Replacement Therapy, Pulmonary Edema
C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19
The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19…
- Conditions
- Continuous Renal Replacement Therapy, Pulmonary Edema, COVID-19
- Trial name
- NCT04537975
- Testing
- C2Rx, Standard of Care (SOC)
- Sponsor
- SeaStar Medical
Coronavirus Disease 2019 (COVID-19)
Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.
- Trial name
- NCT05364671
- Testing
- Raphamin
- Where
- 36 sites in Russia
- Volunteers
- 771 people
- Sponsor
- Materia Medica Holding
Covid19
the Safety and Efficacy of Meplazumab in Patients With COVID-19
This is a multicenter, double-blind, randomized, placebo-controlled phase 2/3 clinical study. Based on the results of the Phase I clinical study, one repeat dose group and one placebo group are used for the standard treatment of…
- Trial name
- NCT05113784
- Testing
- Meplazumab for Injection, Sterile normal saline (0.9%)
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19, Rabies
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.
- Trial name
- NCT05453487
- Testing
- coadministration, COVID-19 vaccine, rabies vaccine
- Where
- 2 sites in China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19
A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection
This is a multicenter, open-label, controlled, randomized phase 2 study designed to evaluate the safety and efficacy profile of GNS561 in patients with COVID-19.
- Trial name
- CureCovid-2019 (NCT04637828)
- Testing
- GNS561
- Where
- France
- Volunteers
- 178 people
- Sponsor
- Genoscience Pharma
COVID-19
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
This study is a randomized and controlled phase Ⅳ clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04993365
- Testing
- Experimental Group, Control Group
- Where
- 2 sites in China
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Covid-19
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
- Trial name
- NCT04523181
- Testing
- Antroquinonol
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 124 people
- Sponsor
- Golden Biotechnology Corporation
COVID-19
Vocal Feature Analysis Algorithm for COVID-19 Detection
This is an observational, prospective, non-randomized, non-significant risk study collecting voice recordings from subjects who are being tested for COVID-19 by laboratory analysis of specimens obtained by nasal or…
- Trial name
- NCT04418544
- Testing
- Device used to record voice for screening
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Soniphi LLC
SARS-CoV-2, Covid-19
Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test
The SARS-CoV-2 Antigen Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the SARS-CoV-2 Antigen Rapid Test assay will be assessed by comparison to a reference method.
- Conditions
- SARS-CoV-2, Covid-19, Coronavirus
- Trial name
- NCT04808921
- Testing
- Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test
- Where
- United States
- Sponsor
- Sky Medical Supplies & Equipments, LLC
COVID-19
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection
The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo.
- Trial name
- NCT04666441
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 57 sites in United States
- Volunteers
- 1,149 people
- Sponsor
- Regeneron Pharmaceuticals
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Renal Impairment
Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
This is a Phase 1, non-randomized, open-label, 2-part study to investigate the effect of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF-07321332 in combination with the PK…
- Trial name
- NCT04909853
- Testing
- PF-07321332/ritonavir
- Where
- 5 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV2 Infection (COVID-19), URTI - Viral Upper Respiratory Tract Infection
Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load.
Prospective, randomized, controlled, multicenter, parallel clinical trial to assess the efficacy of seawater nasal wash to relieve COVID-19 and URTIs nasal symptoms and reduce intranasal viral load in subjects with mild to…
- Trial name
- SeaCare (NCT04916639)
- Testing
- Device: Physiomer undiluted seawater nasal spray
- Where
- France
- Volunteers
- 370 people
- Sponsor
- Laboratoire de la Mer
COVID-19, SARS-CoV-2
Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants
AZD3152 is being evaluated for administration to prevent COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD3152 as well as relevant data on the PK, PD (as the neutralising…
- Trial name
- NCT05932641
- Testing
- AZD3152 (Cohort 1), AZD3152 (Cohort 2), AZD3152 (Cohort 3)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.